Business · 03/12/2003Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for STRATTERA Patent Extension
Summary
The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of STRATTERA, a human drug product, as required by law, following a submission to the Director of Patents and Trademarks at the Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →